In the past decade, there has been increased interest in the therapeutic disruption of the IKK/NF-κB pathway by using various approaches ranging from genetic manipulation to the development of pharmacologic inhibitors of IKK for inflammatory and autoimmune diseases [90,91]. The gene discussed is NFKB1; the disease is autoimmune disease.